Trial Profile

A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Oct 2023 Results presented at the 31st United European Gastroenterology Week
17 Oct 2023 Results of subgroup analysis assessing Clinical Outcomes and Biomarker Normalisation Response at Week 16 in Patients with Inadequate Response or Intolerance to Prior Biologics presented at the 31st United European Gastroenterology Week
17 Oct 2023 Results assessing Pharmacokinetics, Exposure Response Relationships, and Immunogenicity in Crohns Disease Patients with Ustekinumab Secondary Loss of Response Following Ustekinumab IV Re Induction from the Week 16 presented at the 31st United European Gastroenterology Week

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com